These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 18805512)

  • 41. Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
    Sallmyr A; Tomkinson AE; Rassool FV
    Blood; 2008 Aug; 112(4):1413-23. PubMed ID: 18524993
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of histone H2AX increases sensitivity of immortalized mouse fibroblasts to the topoisomerase II inhibitor etoposide.
    Donà F; Prosperi E; Savio M; Coppa T; Scovassi AI; Mondello C
    Int J Oncol; 2008 Sep; 33(3):613-21. PubMed ID: 18695893
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The G2-phase decatenation checkpoint is defective in Werner syndrome cells.
    Franchitto A; Oshima J; Pichierri P
    Cancer Res; 2003 Jun; 63(12):3289-95. PubMed ID: 12810661
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Accumulation of Werner protein at DNA double-strand breaks in human cells.
    Lan L; Nakajima S; Komatsu K; Nussenzweig A; Shimamoto A; Oshima J; Yasui A
    J Cell Sci; 2005 Sep; 118(Pt 18):4153-62. PubMed ID: 16141234
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Werner syndrome helicase (WRN), nuclear DNA helicase II (NDH II) and histone gammaH2AX are localized to the centrosome.
    Zhang S; Hemmerich P; Grosse F
    Cell Biol Int; 2007 Oct; 31(10):1109-21. PubMed ID: 17498979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
    Stahl M; Kasimir-Bauer S; Harstrick A
    Anticancer Drugs; 1997 Aug; 8(7):671-6. PubMed ID: 9311443
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH; Andersson BS; Nelson JA
    Cancer Biochem Biophys; 1990 Jan; 11(1):23-30. PubMed ID: 2159843
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
    Adachi N; Suzuki H; Iiizumi S; Koyama H
    J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
    Choi YJ; Rho JK; Lee SJ; Jang WS; Lee SS; Kim CH; Lee JC
    J Cancer Res Clin Oncol; 2009 Aug; 135(8):1047-53. PubMed ID: 19148680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. WRN, the protein deficient in Werner syndrome, plays a critical structural role in optimizing DNA repair.
    Chen L; Huang S; Lee L; Davalos A; Schiestl RH; Campisi J; Oshima J
    Aging Cell; 2003 Aug; 2(4):191-9. PubMed ID: 12934712
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of WRN in DNA repair is affected by post-translational modifications.
    Kusumoto R; Muftuoglu M; Bohr VA
    Mech Ageing Dev; 2007 Jan; 128(1):50-7. PubMed ID: 17116323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RECQL5 plays co-operative and complementary roles with WRN syndrome helicase.
    Popuri V; Huang J; Ramamoorthy M; Tadokoro T; Croteau DL; Bohr VA
    Nucleic Acids Res; 2013 Jan; 41(2):881-99. PubMed ID: 23180761
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
    Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
    Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
    Kao YH; Hsieh HP; Chitlimalla SK; Pan WY; Kuo CC; Tsai YC; Lin WH; Chuang SE; Chang JY
    Anticancer Drugs; 2008 Feb; 19(2):151-8. PubMed ID: 18176111
    [TBL] [Abstract][Full Text] [Related]  

  • 56. p21CDKN1A allows the repair of replication-mediated DNA double-strand breaks induced by topoisomerase I and is inactivated by the checkpoint kinase inhibitor 7-hydroxystaurosporine.
    Furuta T; Hayward RL; Meng LH; Takemura H; Aune GJ; Bonner WM; Aladjem MI; Kohn KW; Pommier Y
    Oncogene; 2006 May; 25(20):2839-49. PubMed ID: 16407843
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
    Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
    Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of biphasic DNA double strand breaks and activation of multiple repair protein complexes by DNA topoisomerase I drug 7-ethyl-10-hydroxy-camptothecin.
    Wu J; Yin MB; Hapke G; Tóth K; Rustum YM
    Mol Pharmacol; 2002 Apr; 61(4):742-8. PubMed ID: 11901212
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.